Skip to main content
logo
Radiopharm Theranostics logo
Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
1.110
-0.040 (-3.48%)
At close: Oct 8, 2026, 4:00 PM EDT
1.000
-0.110 (-9.91%)
Pre-market: Oct 9, 2026, 5:17 AM EDT

Radiopharm Theranostics Financials Overview

Millions AUD. Fiscal year is Jul - Jun.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Revenue
12.8712.87131.596.21-
Revenue Growth
-23.28%-1.05%716.81%-74.37%--
Gross Profit
-34.34-34.34-18.11-20.02-13.32-7.49
Operating Income
-52.96-52.96-34.64-35.69-28.59-19.93
Net Income
-56.95-56.95-38.34-47.95-34.61-30.42
Earnings Per Share
-0.02-0.02-0.02-0.12-0.11-0.17
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Cash & Investments
4.144.1429.1218.5811.726.98
Total Debt
------
Net Cash (Debt)
4.144.1429.1218.5811.726.98
Net Cash Growth
-88.01%-85.79%56.75%58.77%-56.64%-
Net Cash Per Share
0.000.000.010.050.040.15

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Cash Flow
-52.78-52.78-36.65-22.98-23.2-9.91
Capital Expenditures
-----0.05-0
Free Cash Flow
-52.78-52.78-36.65-22.98-23.25-9.91
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Gross Margin
-266.89%-266.89%-139.27%--214.52%-
Operating Margin
-411.63%-411.63%-266.43%-2242.42%-460.41%-
Pretax Margin
-442.25%-442.25%-294.10%-3006.19%-556.75%-
Profit Margin
-442.67%-442.67%-294.90%-3012.25%-557.36%-
FCF Margin
-410.28%-410.28%-281.85%-1443.39%-374.36%-

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingOct '26 Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
PS Ratio
1.695.234.0010.995.74-